What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Antibiotics
His primary scientific interests are in Internal medicine, Adverse effect, Randomized controlled trial, Intensive care medicine and Meta-analysis.
His Internal medicine research incorporates themes from Antibiotics, Antibacterial agent and Surgery.
His Adverse effect research includes themes of Placebo, Discontinuation, Typhoid fever and Breast cancer.
The various areas that he examines in his Randomized controlled trial study include Clinical trial, Community-acquired pneumonia, Colistin, Physical therapy and Pneumococcal pneumonia.
His Intensive care medicine research incorporates elements of Observational study, Medical prescription, Combination therapy and Drug.
The study incorporates disciplines such as Endocrinology, Quality of life, Immunology, Pharmacotherapy and Dose-dense chemotherapy in addition to Meta-analysis.
His most cited work include:
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis (1203 citations)
- Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis (426 citations)
- β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials (393 citations)
What are the main themes of his work throughout his whole career to date?
Leonard Leibovici focuses on Internal medicine, Intensive care medicine, Antibiotics, Randomized controlled trial and Surgery.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Bacteremia.
His Intensive care medicine research is multidisciplinary, incorporating elements of Clinical trial, Febrile neutropenia, Neutropenia, Decision support system and Combination therapy.
In Antibiotics, Leonard Leibovici works on issues like Pediatrics, which are connected to Epidemiology.
As a member of one scientific family, Leonard Leibovici mostly works in the field of Randomized controlled trial, focusing on Colistin and, on occasion, Meropenem.
His Adverse effect study integrates concerns from other disciplines, such as Placebo and Discontinuation.
He most often published in these fields:
- Internal medicine (76.65%)
- Intensive care medicine (42.42%)
- Antibiotics (32.26%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (76.65%)
- Randomized controlled trial (31.19%)
- Odds ratio (18.00%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Randomized controlled trial, Odds ratio, Retrospective cohort study and Colistin.
His is doing research in Urinary system, Confidence interval, Mortality rate, Cohort and Adverse effect, both of which are found in Internal medicine.
His work deals with themes such as Relative risk, Discontinuation, Emergency medicine and Patient experience, which intersect with Adverse effect.
His studies deal with areas such as Observational study, Meta-analysis, Subgroup analysis, Combination therapy and Polymyxin as well as Randomized controlled trial.
His Odds ratio research is multidisciplinary, incorporating elements of Multivariate analysis and Antibiotics.
His Antibiotics study combines topics from a wide range of disciplines, such as Medical microbiology, Pseudomonas aeruginosa and Intensive care medicine.
Between 2016 and 2021, his most popular works were:
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis (1203 citations)
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial (198 citations)
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial (198 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibiotics
- Surgery
Leonard Leibovici mostly deals with Internal medicine, Adverse effect, Antibiotics, Randomized controlled trial and Mortality rate.
His studies in Odds ratio, Urinary system, Meta-analysis, Interquartile range and Pneumonia are all subfields of Internal medicine research.
His study looks at the relationship between Meta-analysis and topics such as Relative risk, which overlap with Cochrane Library and Secondary infection.
Leonard Leibovici interconnects Clinical trial, Discontinuation and Confidence interval in the investigation of issues within Adverse effect.
His research in Antibiotics tackles topics such as Pseudomonas aeruginosa which are related to areas like Bacilli, Microbiology and Drug.
In his study, which falls under the umbrella issue of Antibiotic resistance, Intensive care medicine is strongly linked to Carbapenem-resistant enterobacteriaceae.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
